This episode looks at what happens when a drug meets the body’s chemical processing plants. Drug metabolism is framed not as simple breakdown, but as biotransformation—a set of enzymatic decisions that can inactivate drugs, activate pro-drugs, generate toxic intermediates, or change duration of action. We explore why metabolism is central to variability, interactions, and organ-specific risk, and why understanding pathways matters more than memorising enzyme lists.

Key takeaways you’ll build and reuse throughout the series:

* Metabolism as transformation, not disposal: Phase I and Phase II reactions as chemical editing steps with clinical consequences.

* The liver as coordinator, not monopolist: extrahepatic metabolism and why location matters.

* Enzyme capacity and competition: saturation, induction, inhibition, and their role in non-linear kinetics.

* Bioactivation and toxicity: when metabolism creates harm rather than neutralising it.

* Translating pathways to practice: anticipating interactions, dose adjustments, and patient-specific risk.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe